Journal article

Publication year: 2014

Pages: 317-325

Journal: Journal of Thrombosis and Thrombolysis

Volume number: 37

Issue number: 3

ISSN: 0929-5305

eISSN: 1573-742X

DOI Link: https://doi.org/10.1007/s11239-013-0921-0

Publisher: Springer

Abstract: 
Factor VII Activating Protease (FSAP) activates factor VII (FVII) as well as pro-urokinase (uPA). Our goal was to evaluate the relation between plasma levels of FSAP and clinical instability in atrial fibrillation (AF) and possible effects of oral omega-3 fatty acids (FA) supplements. 101 patients with persistent AF were analyzed in the OMEGA-AF Study. Plasma FSAP levels were measured at baseline and after 12 weeks of treatment with omega-3 FA. The median FSAP antigen concentration, in contrast to FSAP activity, was higher in patients with persistent AF. The maintenance of SR after successful cardioversion (CV) did not lead to a normalization of FSAP concentration. Supplementation with omega-3 FA but not placebo significantly reduced elevated FSAP concentration. Furthermore, elevated FSAP levels did not indicate a significantly increased risk of recurrence of AF after electrical CV or cardiovascular clinical events during 1 year of follow-up. Plasma FSAP concentration was increased in patients with AF and may be involved in the pathogenesis of this condition. The possible effects of omega-3 FA on clinical AF potential could be linked with modulation of circulating FSAP levels.

Harvard Citation style: Parahuleva, M., Kanse, S., Hoelschermann, H., Zheleva, K., Zandt, D., Worsch, M., et al. (2014) Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study, Journal of Thrombosis and Thrombolysis, 37(3), pp. 317-325. https://doi.org/10.1007/s11239-013-0921-0

APA Citation style: Parahuleva, M., Kanse, S., Hoelschermann, H., Zheleva, K., Zandt, D., Worsch, M., Parviz, B., Guettler, N., Tillmanns, H., Boening, A., & Erdogan, A. (2014). Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study. Journal of Thrombosis and Thrombolysis. 37(3), 317-325. https://doi.org/10.1007/s11239-013-0921-0